Back to results
US 11,230,604 B2Granted
Antibodies against human CD38
AssigneeGenmab A/S
InventorsMichel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
Life of this patent
Estimating the term…
Abstract
Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
Claims119
A nucleic acid encoding an antibody that binds to human CD38 as set forth in SEQ ID NO:
- 52, wherein the antibody comprises:
- (i) a VH CDR1 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 3, 8, 13, 18, and 23, a VH CDR2 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 4, 9, 14, 19, and 24, a VH CDR3 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 5, 10, 15, 20, and 25, a VL CDR1 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 28, 33, 38, 43, and 48, a VL CDR2 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 29, 34, 39, 44, and 49, and a VL CDR3 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 30, 35, 40, 45, and 50,
- (ii) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 3, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 4, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 5, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 28, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 29, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 30,
- (iii) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 8, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 9, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 10, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 33, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 34, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 35,
- (iv) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 13, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 14, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 15, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 38, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 39, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 40,
- (v) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 18, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 19, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 20, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 43, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 44, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 45, or
- (vi) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 23, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 24, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 25, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 48, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 49, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 50.
40 more elements
A nucleic acid comprising one or more nucleotide sequences selected from the group consisting of SEQ ID NOs:
- 1, 6, 11, 16, 21, 26, 31, 36, 41, and 46.
A nucleic acid encoding an antibody that binds to CD38, wherein the antibody comprises a VH region comprising any one of the sequences as set forth in SEQ ID NOs:
- 2, 7, 12, 17, and 22, and a VL region comprising any one of the sequences as set forth in SEQ ID NOs:
- 27, 32, 37, 42, and 47.
A combination of nucleic acids encoding an antibody that binds to CD38, wherein the antibody comprises:
- (i) a VH CDR1 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 3, 8, 13, 18, and 23, a VH CDR2 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 4, 9, 14, 19, and 24, a VH CDR3 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 5, 10, 15, 20, and 25, a VL CDR1 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 28, 33, 38, 43, and 48, a VL CDR2 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 29, 34, 39, 44, and 49, and a VL CDR3 having the sequence as set forth in any of the sequences SEQ ID NOs:
- 30, 35, 40, 45, and 50,
- (ii) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 3, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 4, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 5, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 28, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 29, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 30,
- (iii) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 8, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 9, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 10, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 33, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 34, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 35,
- (iv) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 13, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 14, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 15, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 38, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 39, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 40,
- (v) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 18, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 19, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 20, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 43, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 44, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 45, or
- (vi) a VH CDR1 having the sequence as set forth in SEQ ID NO:
- 23, a VH CDR2 having the sequence as set forth in SEQ ID NO:
- 24, a VH CDR3 having the sequence as set forth in SEQ ID NO:
- 25, a VL CDR1 having the sequence as set forth in SEQ ID NO:
- 48, a VL CDR2 having the sequence as set forth in SEQ ID NO:
- 49, and a VL CDR3 having the sequence as set forth in SEQ ID NO:
- 50.
39 more elements
A combination of nucleic acid encoding an antibody that binds to CD38, wherein the antibody comprises a VH region comprising any one of the sequences as set forth in SEQ ID NOs:
- 2, 7, 12, 17, and 22, and a VL region comprising any one of the sequences as set forth in SEQ ID NOs:
- 27, 32, 37, 42, and 47.
A combination of nucleic acids encoding an antibody that binds to CD38, wherein the antibody comprises:
- (i) a VH region comprising the sequence as set forth in SEQ ID NO:
- 2, and a VL region comprising the sequence as set forth in SEQ ID NO:
- 27,
- (ii) a VH region comprising the sequence as set forth in SEQ ID NO:
- 7, and a VL region comprising the sequence as set forth in SEQ ID NO:
- 32,
- (iii) a VH region comprising the sequence as set forth in SEQ ID NO:
- 12, and a VL region comprising the sequence as set forth in SEQ ID NO:
- 37,
- (iv) a VH region comprising the sequence as set forth in SEQ ID NO:
- 17, and a VL region comprising the sequence as set forth in SEQ ID NO:
- 42, or
- (v) a VH region comprising the sequence as set forth in SEQ ID NO:
- 22, and a VL region comprising the sequence as set forth in SEQ ID NO:
- 47.
12 more elements
Dependencies are inferred from the claim text.